Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | Chief Legal Officer, Secretary | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 241,416 |
Reported balance
After 2026-08-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 241,416 · Balance 241,416 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F2: The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on August 18, 2027; 3/48 of the RSUs vesting on November 18, 2027 and each November 18 thereafter; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; and 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan"))). |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.66 · Expires 2036-08-09 | Direct | 127,118 |
Reported balance
After 2026-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-10 · Grant · Acquired 127,118 · Balance 127,118 F3: The shares subject to the option shall vest over 4 years with 25% vesting on August 10, 2027 and 1/48 of the shares vesting each month thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the 2021 Plan)). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2: The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on August 18, 2027; 3/48 of the RSUs vesting on November 18, 2027 and each November 18 thereafter; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; and 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan"))).
F3: The shares subject to the option shall vest over 4 years with 25% vesting on August 10, 2027 and 1/48 of the shares vesting each month thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the 2021 Plan)).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 127,118 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0002141966-26-000002 · form4-08122026_100817.xml · derivative · entry 2 Feuchtwang Ilan · CIK 0002141966 · Chief Legal Officer, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,118 Underlying: Common Stock · 127,118 shares Expires 2036-08-09 F3 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 25% vesting on August 10, 2027 and 1/48 of the shares vesting each month thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the 2021 Plan)). Read SEC document |
| August 10, 2026 Filed Aug 12, 2026 22:31 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 241,416 | $0.00 | $0.00 |
DisclosureSEC source: 0002141966-26-000002 · form4-08122026_100817.xml · derivative · entry 1 Feuchtwang Ilan · CIK 0002141966 · Chief Legal Officer, Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,416 Underlying: Common Stock · 241,416 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on August 18, 2027; 3/48 of the RSUs vesting on November 18, 2027 and each November 18 thereafter; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; and 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan"))). F2 · derivative.expiration_date: The RSUs shall vest and settle into common stock over 4 years, with 12/48 of the RSUs vesting on August 18, 2027; 3/48 of the RSUs vesting on November 18, 2027 and each November 18 thereafter; 4/48 of the RSUs vesting on March 10, 2028 and each March 10 thereafter; 2/48 of the RSUs vesting on May 18, 2028 and each May 18 thereafter; and 3/48 of the RSUs vesting on August 18, 2028 and each August 18 thereafter, until fully vested (in each case, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Invesntive Plan (the "2021 Plan"))). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.